|
|
||||||||
1 From the National Vision Research Institute of Australia, Carlton, Victoria, Australia; and the 2 Department of Optometry and Vision Sciences, University of Melbourne, Melbourne, Victoria, Australia.
| Abstract |
|---|
|
|
|---|
METHODS. The expression of the epithelial ETS transcription factors ELF5, ESE3, and ELF3 was assessed by RT-PCR in the human RPE cell lines D407 and hTERT-RPE1. The full-length coding sequence of rat Elf3 was isolated with 3' rapid amplification of cDNA ends (RACE) and degenerative primers, and its expression was determined in various rat tissues, by RT-PCR and real-time PCR. A polyclonal ELF3 antibody produced from a C-terminal peptide was used to observe the distribution of the transcription factor within the retina. To assess the possible ELF3 regulation of the TIMP3 promoter, transient transfection assays were performed. Promoter activity was determined with a firefly luciferase reporter gene construct.
RESULTS. The epithelium-specific ETS transcription factor ELF3 was expressed in the D407 and hTERT-RPE1 cell lines. Neither ESE3 nor ELF5 was detected in the RPE. The cloning of rat Elf3 produced two splice variants, designated Elf3a (1786 bp) and Elf3b (1855 bp). The larger form, Elf3b, contained a 69-bp insert in the coding sequence, which showed high homology to a similar insert previously identified in murine Elf3. Both splice variants were expressed in rat lung, kidney, liver, and retina, but were absent in heart tissue. Real-time PCR analysis showed the retina to contain high levels of Elf3, which was subsequently localized to the RPE. Elf3 upregulated the TIMP3 promoter, with Elf3a and -3b inducing an approximate sixfold increase in activity.
CONCLUSIONS. The ELF3 transcription factor is highly expressed in the RPE and can regulate important ocular genes, such as TIMP3, in vitro. The specific expression of ELF3 in the RPE may reflect an important role for this transcription factor in retinal function. Furthermore, its regulation of TIMP3 may have implications for degenerative retinal diseases, such as age-related macular degeneration.
| Introduction |
|---|
|
|
|---|
Transcription factors are known to regulate gene expression by binding directly to promoter sites within DNA or to other transcription factors. During tissue development, these factors are the main determinants of final cellular identity. Within the eye, several transcription factors are known to be critical to proper ocular development. PAX6 has been described as the master control gene in eye formation,5 whereas CHX10 has been implicated in retinal development.6 Other transcription factors such as those in the Fos and Jun families,7 MITF8 and CRX9 are also critical to eye formation. The importance of these factors is further emphasized by the fact that mutations within transcription factor genes have been associated with the development of ocular disease.9
The ETS family of transcription factors, which presently number more than 30, are important regulators of hematopoiesis,10 angiogenesis,11 cell differentiation,12 and organogenesis.13 Originally identified because of their homology to the v-ets oncogene,14 all members of the family share a highly conserved DNA-binding domain known as the ETS domain and recognize the GGA(A/T) core sequence in the promoters and enhancers of various cellular genes. The importance of the ETS domain to protein function is illustrated by its high degree of conservation (49% identity) between human and Drosophila.15 In addition to their role in development, ETS factors have been implicated in several diseases such as Down syndrome,16 Alzheimers disease,17 and tumorigenesis.11
Several of the ETS transcription factor family are specifically expressed in epithelial cells. ELF3 (ERT/ESX/ESE1) was the first described in human breast cancer cells, but has subsequently been identified in a wide range of epithelial cells.18 19 Three other epithelial ETS factors, ELF5 (ESE2),20 ESE3,21 and PDEF (Pse),22 23 have also been identified recently; however, these factors have a more restricted pattern of expression. The presence of these ETS transcription factors may be critical for the epithelial phenotype, with alterations in expression associated with malignant transformation.19
There has been only limited investigation into the presence and role of ETS factors within the vertebrate eye. Recently, Yoshida et al.24 have reported the presence of Elf3 in mouse corneal epithelium. Its expression parallels that of the differentiation marker, K12 keratin and appeared critical for epithelial differentiation within the cornea. Earlier work by ONeal et al.25 implicated another two ETS domain proteins, pointed and yan, in Drosophila photoreceptor development. Because ETS function is highly conserved between species,26 these transcription factors may have important roles in the ocular development of higher organisms.
ETS transcription factors may also regulate genes potentially involved in retinal disease. Of particular interest is the tissue inhibitor of metalloproteinase 3 (TIMP3) gene, which has shown elevated levels in retinitis pigmentosa (RP),27 Sorbys fundus dystrophy (SFD),27 and age-related macular degeneration (ARMD).28
TIMP3, unlike the other members of the TIMP family, is an insoluble component of the extracellular matrix (ECM). It is synthesized in the RPE and deposited in Bruchs membrane, where it regulates ECM turnover and limits choroidal neovascularization. Mutations within the TIMP3 gene are known to lead to the development of autosomal dominant SFD.29 Because SFD and ARMD have a similar etiology, TIMP3 may also play a role in the progression of the age-related condition. However, no mutations have been found in patients with ARMD, suggesting that other mechanisms are involved in accumulation of TIMP3 and the resultant changes in the ECM that are observed in this disease. The upregulation of TIMP3 by transcription factors could provide such a mechanism.
The purpose of the present study was to identify whether epithelial ETS transcription factors are expressed in the RPE. The identification of retinal transcription factors may provide an insight, not only into RPE regulation, but also into the cellular disruption that occurs in retinal diseases such as ARMD.
| Materials and Methods |
|---|
|
|
|---|
Cell Lines and Culture
The transformed human RPE cell line D407 was grown in Dulbeccos modified Eagles medium (DMEM; Gibco-Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (FCS), 100 U/mL penicillin, and 100 µg/mL streptomycin (CSL, Melbourne, Australia). The telomerase-immortalized human RPE cell line, hTERT-RPE1 (Clontech, Palo Alto, CA), was grown in DMEM-F12 (Gibco-Life Technologies) containing 10% FCS, 0.348% Na2HCO3, 100 U/mL penicillin, and 100 µg/mL streptomycin. Cell lines were maintained in a humidified incubator at 5% CO2 and 37°C. Confluent cell monolayers were passaged using a 1% (wt/vol) trypsin-EDTA solution (CSL).
Isolation and Characterization of Rat Elf3 cDNA
The 3' coding sequence of rat Elf3 was determined using the rapid amplification of cDNA ends (RACE) system (Life Technologies). The initial RACE reaction used a specific rat Elf3 primer (5'-ggagatcctggaacgggtggatgg-3') and a universal primer (UAP; Life Technologies). The subsequent product was reamplified with a nested primer (5'-ctcgtctacaagtttggcaaaaac-3'). The specific Elf3 and nested primers were derived from a rat expressed sequence tag (EST) that showed a high homology with the human and murine ELF3 sequences. Additional 5' coding sequence was determined with a degenerate ATG-spanning oligonucleotide (5'-atggcngcnacntgygarat-3'). All cDNA sequences were confirmed by automated sequencing of both strands.
The full rat Elf3 coding sequence was cloned using the degenerate oligonucleotide and a primer within the 3' untranslated region (5'-ctgacccttaattctgactctctccaacc-3'). The 1192-bp (Elf3a) and 1123-bp (Elf3b) products were subcloned into a plasmid vector (pGEM-T; Promega Corp., Madison, WI) and subsequently cloned into the NotI site of the expression vector pcDNA3.1 (Invitrogen, Carlsbad, CA), yielding the constructs rElf3a/pcDNA3.1 and rElf3b/pcDNA3.1.
RNA Isolation and RT-PCR
Total RNA was isolated from individual rat tissues (1030 mg) and the D407 and hTERT-RPE1 cell lines (0.51 x 107 cells) using an extraction kit (RNeasy mini kit; Qiagen, Chatsworth, CA). The retinal samples included tissue from the posterior eye cup. Total RNA from the human breast and prostate cancer cell lines, T47D and PC3, were used as the positive control for ETS transcription factor expression. RT-PCR was performed on 0.5 µg RNA (Omniscript RT; Qiagen) using an oligo dT primer. Subsequent amplification on a thermal cycler (PCR Express; Hybaid, Ashford, UK) used HotStarTaq DNA polymerase (Qiagen) and intron-spanning primers for the ETS family members hELF3, hESE3, hELF5, and rElf3 (Table 1)
. The amplification protocol consisted of 95°C (15 minutes), followed by 30 cycles of 94°C (10 seconds), 58°C (30 seconds), and 72°C (1 minute). The Elf3a and -3b splice variants were amplified from rat tissues with a 35-cycle protocol.
|
Elf3 Polyclonal Antibody Production
New Zealand White rabbits were challenged with an Elf3 peptide sequence (VDGRRLVYKFGKNSSGWKE) linked to a diphtheria toxin carrier (Chiron Technologies, Melbourne, Australia). Antibodies were affinity purified using a recombinant human ELF3 linked gel (Sepharose-4B; Amersham Pharmacia Biotech, Piscataway, NJ). The recombinant protein was generated using the His-tag expression vector pQE30 and purified on a separation column (Ni-NTA Superflow; Qiagen), with a denaturing protocol.19
Western Blot Analysis
Rat tissue nuclear extracts were isolated in a two-step lysis protocol. Respective tissues were washed with PBS (7.2 mM Na2HPO4, 2.8 mM NaH2PO4 [pH 7.2], and 0.15M NaCl) and homogenized in a cytoplasmic lysis buffer (10 mM Tris-HCl [pH 8], 5 mM KCl, 2 mM MgCl2, and 0.5% Nonidet P-40). Cell nuclei were pelleted (22,000g), washed with the cytoplasmic lysis buffer, and resuspended in SDS sample buffer.
Soluble proteins were separated by SDS-PAGE,30 and Western blot analysis was performed according to the method of Towbin and Gordan.31 The Elf3 antibody was used at a concentration of 1 µg/mL, and a sheep anti-rabbit HRP conjugate (Silenus, Melbourne, Australia) was used as the secondary antibody. The membrane was developed with a luminescence detection kit (ECL Plus; Amersham, Buckinghamshire, UK).
Immunohistochemistry
Hybrid-ready rat eye sections (Novagen, Madison, WI) were deparaffinized, rehydrated, immersed in 0.01 M sodium citrate buffer (pH 6.0), and heated for 10 minutes.32
Tissue sections were blocked with 20% sheep serum for 1 hour, rinsed, and incubated overnight in PBS containing 1% BSA, 1% rat serum, 1% sheep serum, and 5 µg/mL Elf3 antibody. Sections were subsequently incubated with a sheep anti-rabbit AP conjugate (Silenus), followed by a rabbit anti-APAAP conjugate (Sigma Chemical Co., St. Louis, MO). The signal was detected using fast blue BB and sections were counterstained with periodic acid-Schiff stain (Sigma). For the blocking control, the Elf3 antibody was incubated for 1 hour with a 200-fold molar excess of immunizing peptide.
Construction of Luciferase Reporter Vectors
A 3.5-kbp fragment, containing the human TIMP3 promoter was isolated from the bacterial artificial chromosome (BAC) bK766E1 after BamHI digestion. This fragment was cloned into a vector (pGem3Zf(-); Promega Corp.) and a 1210-bp fragment subsequently isolated after digestion with EcoICRI (Promega Corp.). The TIMP3 promoter fragment (-932 to +278) was finally blunt-end cloned into the HindIII site of a luciferase reporter vector (pGL3basic; Promega Corp.) yielding TIMP3-932luc.
A fragment corresponding to the human E-cadherin promoter (-970 to +30) was isolated by PCR. Forward (5'-tcacgcctgtaatccaacac-3') and reverse (5'-tcacaggtgctttgcagttc-3') primers were designed with reference to the published sequence.33 The 1000-bp product was subcloned into a plasmid vector (pGEM-T; Promega Corp.) before being cloned into an expression vector (pGL3basic; Promega Corp.), as described earlier. This construct was designated Ecad-970luc.
The sequence of both reporter constructs were verified by automated DNA sequencing.
Transient Transfection Assays
Human RPE cells (hTERT-RPE1) were transfected with a lipid-based transfection reagent (Qiagen). Equal amounts (0.2 µg) of the TIMP3-932luc plasmid and rElf3a/pcDNA3.1, rElf3b/pcDNA 3.1, or the empty expression vector pcDNA3.1 was added. For control experiments, the E-cadherin promoter construct (Ecad-970luc) was used in place of TIMP3-932luc. Cells were harvested after 24 hours and lysed (25 mM Tris-phosphate [pH 7.8], and 10 mM MgCl2, 1 mM EDTA, 1 mM dithiothreitol, 15% glycerol, and 1% Triton X-100). The cell extract was added to an assay buffer (lysis buffer without 1 mM dithiothreitol, with 1.25 mM adenosine triphosphate [ATP] and 75 µM luciferin; Promega Corp.) and luciferase activity estimated on a luminometer (Lumat LB 9507; EG&G Berthold, Bad Wildbad, Germany). Protein content was determined with a protein assay kit (Dc; Bio-Rad, Richmond, CA). The mean ± SD was obtained from triplicate samples and the data compared with ANOVA.
| Results |
|---|
|
|
|---|
As observed in Figure 1 , both human RPE cell lines contained specific message for ELF3, whereas neither expressed ESE3 or ELF5. The spontaneously transformed D407 cell line appeared to express significantly more ELF3 than hTERT-RPE1; however, semiquantitative PCR must be performed to estimate the difference in expression. Although ELF3 expression has been reported in tissues such as liver, lung, and kidney,19 this is the first evidence of expression in the retina. The human breast (T47D) and prostate (PC3) cancer cell lines are known to express ELF5, ELF3, ESE3, and ELF3, ESE3, respectively, and were used as positive controls.19 20
|
|
Elf3 expression in various rat tissues was quantified by real-time PCR, which provides an accurate measure of gene expression.35 Elf3 was detected in lung, kidney, liver, and retina, yet was absent in heart (Fig. 3A) . Previous reports have found that heart tissue does not express ELF3.19 Although rat retina contains significant quantities of this transcription factor, its levels are approximately 50% lower than those found in lung and kidney. These tissues have previously been reported to contain high levels of ELF3.19
|
Because commercial Elf3 antibodies were unsuitable for use in rat tissues, a polyclonal antibody was produced after challenge from a C-terminal peptide to Elf3. The 19-amino-acid peptide (368Val386Glu) is totally conserved among human, murine, and rat Elf3. The Western blot in Figure 4 shows the antibody to be specific for Elf3, with an approximate 43-kDa band detected for the human recombinant protein and the rat tissue samples.
|
|
|
| Discussion |
|---|
|
|
|---|
ELF3 was expressed in rat retinal tissue and in the human RPE cell lines, D407 and hTERT-RPE1. The other epithelial ETS factors, ELF5 and ESE3 were not found in the RPE, reflecting their restricted expression patterns.20 21 22 Histochemical staining of the retina localized the expression predominantly to the RPE, with only weak staining observed in the inner nuclear layer, specifically the horizontal cell bodies. While this staining appeared to be specific, ELF3 expression has not been reported in neuronal cells. In fact, Northern and RNase protection analysis performed by Tymms et al.19 showed that neither fetal nor adult brain expresses ELF3. Neuronal cells, however, express other ETS family members, such as Pet-1 and Er81.37 38 Although cross reactivity with these related transcription factors may have resulted in the apparent horizontal cell localization, it was not observed in the Western blot analysis.
Alternatively spliced products have been reported for many ETS genes, including Ets1, Elk1, and Tel.39 40 41 The larger splice variant (Elf3b) described in this study has an extra 69 bp adjacent to the conserved N-terminal domain (pointed-like). The apparent preference for this transcript, coupled with the high insert homology to murine Elf3b, could reflect a functional significance. A protein motif search showed the insert to contain a potential casein kinase II (CK2) or protein kinase C (PKC) phosphorylation site (SQRD). Phosphorylation of ETS transcription factors is known to regulate many of their functions, such as DNA binding, transcriptional activation, transcriptional repression, and subunit association.42 Furthermore, the proximity of the insert to the pointed-like domain, may potentiate this domains role in dimerization and transactivation.43 44 The presence of a different human ELF3 splice variant may reflect a species-specific regulatory mechanism for this transcription factor.34
As in previous studies, ELF3 was detected in the liver, lung, and kidney, but was absent from the heart.19 Quantification of the relative copy numbers showed lung and kidney to express the highest levels of ELF3, followed by retina and liver. However, because ELF3 is expressed only in epithelial cells, the proportion of epithelia in the various tissues has a large impact on the apparent levels. Whereas the lung and kidney contain high proportions of specialized epithelial cells, the retina has only a single, noninvaginated layer of epithelial cells. It is therefore likely that retinal expression of ELF3 is underestimated. The existence of high expression levels in the RPE could reflect an important role for this factor in retinal gene regulation.
Although the part played by ELF3 in tissue development is yet to be determined, its expression has been associated with mammary gland development and the occurrence of the epithelial phenotype.45 46 ELF3 is known to regulate numerous genes such, as keratin 4, c-met and Erb-B2.12 18 47 Recently, it was also shown to induce expression of the TGF-ß receptor type II.48 The TGF-ß family, including their receptors, are known to play important roles in the development and functioning of the retina.
The in vitro transfections showed ELF3 to upregulate the TIMP3 gene, presumably through one of the identified ETS binding sites. Although previous reports have identified an ETS binding site in the response element for TIMP1,49 this is the first evidence of ELF3 regulation of the TIMP3 gene. TIMP3 is localized to the extracellular matrix and is able to inhibit all the major classes of matrix metalloproteinases (MMPs),50 making it a very powerful modulator of extracellular matrix (ECM) turnover. The ELF3 regulation of TIMP3 would have implications for development, morphogenesis, and tissue remodelling in epithelial cells. Furthermore, because alterations in ECM have been observed in several diseases such as cancer, arthritis, and cardiovascular disease,51 this regulatory mechanism could be of great interest.
In the retina, the accumulation of TIMP3 is thought to play a significant role in the progression of the phenotypically similar SFD and ARMD.27 28 Although the development of SFD has been attributed to several point mutations within the TIMP3 gene, the mechanisms underlying ARMD have yet to be elucidated. ELF3 regulation of TIMP3 may provide such a mechanism. If the regulation observed in vitro is representative of in vivo regulatory properties, then increases in ELF3 expression within the retina would result in an accumulation of TIMP3. Such an accumulation may play a role in the thickening of Bruchs membrane and the progression of ARMD. A similar ELF3-related pathway could also explain the increased TIMP3 levels observed in patients with RP.27 Although this study shows TIMP3 to be under the control of ELF3 in vitro, further work is needed to determine whether such regulation occurs in vivo. Furthermore, the existence of ELF3 within the retina raises the possibility that other genes involved in retinal disease may be under its control.
This study has shown the RPE to express significant quantities of the ETS transcription factor ELF3. Although the role of this factor in retinal development is unclear, there are a number of critical genes that it may regulate. The upregulation of TIMP3 by ELF3 may have implications for the ECM changes observed in diseases such as RP and ARMD.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication November 27, 2001; revised February 11, 2002; accepted February 28, 2002.
Commercial relationships policy: N.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: Andrew Ian Jobling, National Vision Research Institute of Australia, 386 Cardigan Street, Carlton, Victoria 3053, Australia; a.jobling{at}optometry.unimelb.edu.au.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
B. Manavathi, S. K. Rayala, and R. Kumar Phosphorylation-dependent Regulation of Stability and Transforming Potential of ETS Transcriptional Factor ESE-1 by p21-activated Kinase 1 J. Biol. Chem., July 6, 2007; 282(27): 19820 - 19830. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Prescott, K. S. N. Koto, M. Singh, and A. Gutierrez-Hartmann The ETS Transcription Factor ESE-1 Transforms MCF-12A Human Mammary Epithelial Cells via a Novel Cytoplasmic Mechanism Mol. Cell. Biol., June 15, 2004; 24(12): 5548 - 5564. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |